Menu
Oslo, Norway, 10 February 2025: Reference is made to stock exchange announcements by Thor Medical ASA (the "Company") on 24 January 2025 regarding the final results of a subsequent offering (the "Subsequent Offering"), where a total of 10,519,746 new shares in the Company were allocated and resolved issued by the board of directors.
The share capital increase relating to the Subsequent Offering is now registered with the Norwegian Register of Business Enterprises. The Company's share capital is after the registration NOK 62,881,704.20, divided into 314,408,521 shares. Each share has a nominal value of NOK 0.20 and represents one vote in the Company's general meeting.
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the Securities Trading Act.
CONTACTS
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
